Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Horizon Licenses CRISPR/Cas9 Gene Editing Technology from ERS Genomics

Published: Saturday, May 10, 2014
Last Updated: Saturday, May 10, 2014
Bookmark and Share
Horizon has entered into a non-exclusive license agreement with ERS.

Horizon Discovery™ Group plc has announced that it has entered into a non-exclusive license agreement with ERS Genomics Ltd (ERS) to access intellectual property (IP) relating to the CRISPR/Cas9 gene editing system.

Under the terms of the agreement, Horizon has rights to use the technology, which is based on the work of Dr. Emmanuelle Charpentier and her colleagues, for research applications including development and sale of research tools, kits and reagents, performance of research services, creation of genetically modified disease model cell lines, development and production of reference standard material for molecular diagnostics and for internal target identification and validation research efforts.

The acquisition of this important CRISPR IP is in line with the Company’s aims outlined at the time of its IPO and further strengthens Horizon’s long-term position in the market for this cutting edge gene editing technology.

Access to a broader CRISPR IP portfolio will allow the technology to be deployed extensively across Horizon’s products, services and leveraged R&D and further enhance the attractiveness of the Horizon GENESIS™ offering to customers.

“Horizon Discovery’s ambition is to be the market leader in CRISPR technology, and by expanding our portfolio of intellectual property rights in this area we aim to ensure that our customers, both now and in the future, will have unencumbered access to this innovative new gene editing technology,” said Dr. Darrin Disley, Chief Executive Officer of Horizon Discovery Group.

Dr. Disley continued, “We believe that the ERS Genomics IP, based on the work of Dr. Emmanuelle Charpentier and her colleagues, is particularly important and so we are very pleased to be able to add it to our expanding portfolio of patent rights in this area on behalf of our customers.”

Professor Emmanuelle Charpentier was principal co-author on a seminal publication suggesting how the CRISPR/Cas9 system could be adapted from use in bacteria for broad application in mammalian genome editing.

She is currently serving as head of the Department of Regulation of Infectious Disease at the Helmholtz Centre for Infection Research.

Horizon continues to review the gene editing field for further product expansion and IP licensing opportunities.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon and Redx Sign Cancer Research Collaboration
Collaboration to progress Redx Pharma plc’s novel pan-RAF inhibitor program towards out-licensing.
Friday, September 04, 2015
Horizon to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Friday, March 13, 2015
Horizon Discovery Appoints Dr David Smoller as an Executive Director
Company announces the appointment of Dr David Smoller, Chief Business Officer of Horizon, as an Executive Director of the Board, with immediate effect.
Monday, November 03, 2014
Horizon Signs Master Services Agreement for Approximately $1.2 Million
Agreement covers development of molecular reference standards for companion diagnostics.
Friday, September 26, 2014
Horizon Discovery Adds Three Eminent CRISPR Experts to its SAB
Dr. Emmanuelle Charpentier, Dr. J. Keith Joung, and Dr. Feng Zhang join the Company’s panel of expert gene editing advisors.
Tuesday, August 05, 2014
Horizon and OPDC Sign Collaboration Agreement
Horizon CombinatoRx to perform in-vitro cell line screening of OPDC clinical stage development candidates.
Friday, July 25, 2014
Horizon Licenses AAV Gene Delivery Technology from Stanford University
Agreement supplements existing exclusive rAAV gene targeting license from University of Washington.
Thursday, July 03, 2014
Horizon, LGC Awarded Technology Strategy Board Grant
Improving minimally invasive circulating DNA diagnostic assays supports implementation of stratified and personalized intervention strategies.
Tuesday, June 17, 2014
Horizon Discovery Licenses CRISPR Gene Editing Technology
The Company announced it has entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system.
Thursday, June 12, 2014
Horizon Completes Acquisition of CombinatoRx from Zalicus
Acquisition of revenue generating and complementary business establishes Horizon’s headquarters in North America.
Monday, June 02, 2014
Horizon to Acquire CombinatoRx Service Business and Assets from Zalicus
Horizon Discovery Group has agreed to acquire the CombinatoRx service business and related assets from Zalicus Inc for £4.7M.
Thursday, May 15, 2014
Horizon, Sirion Sign Supply and Distribution Agreement
Agreement adds custom and off-the-shelf shRNA and cDNA expression capabilities to Horizon’s offering.
Monday, February 17, 2014
Horizon Discovery and Transgenomic Collaborate
Collaboration agreement aims to develop improved genetic diagnostic tests incorporating state of the art controls.
Thursday, January 16, 2014
Horizon, AstraZeneca Announce Oncology Agreement
Research, collaboration and license agreement to explore a range of oncology-relevant genotypes.
Tuesday, January 07, 2014
Scientific News
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
How to Control Shape, Structure of DNA and RNA
Researchers have used computational modelling to shed light on precisely how charged gold nanoparticles influence the structure of DNA and RNA.
Advancing Genome Editing of Blood Stem Cells
Genome editing techniques for blood stem cells just got better, thanks to a team of researchers at USC and Sangamo BioSciences.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos